Latest Pharma Insights
C&D Pulls Curtain Down On Gummy Vitamin Gambit With Sale To Piping Rock Health
Decision on vitafusion and L’il Critters business planned by end of year, but Piping Rock Health provided incentive for C&D to opt for divestiture.
HBW Insight - December 10, 2025
Decision on vitafusion and L’il Critters business planned by end of year, but Piping Rock Health provided incentive for C&D to opt for divestiture.
HBW Insight - December 10, 2025
Phrontline’s Two-Pronged Shot At Bispecific, Dual-Payload ADCs
To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.
Scrip - December 10, 2025
To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.
Scrip - December 10, 2025
Xeltis Raises €50M To Advance Tissue-Regenerating Dialysis Access As CMS Opens Door To New Options
Xeltis secured €50m to scale and market its aXess vascular access graft, a bioresorbable scaffold that transforms into a patient’s own living vessel. With EU regulatory review underway and US trials advancing, Xeltis sees new US Medicare rules as a major opening for alternative treatments.
Medtech Insight - December 10, 2025
Xeltis secured €50m to scale and market its aXess vascular access graft, a bioresorbable scaffold that transforms into a patient’s own living vessel. With EU regulatory review underway and US trials advancing, Xeltis sees new US Medicare rules as a major opening for alternative treatments.
Medtech Insight - December 10, 2025
Phrontline’s Two-Pronged Shot At Bispecific, Dual-Payload ADCs
To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.
Scrip - December 10, 2025
To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.
Scrip - December 10, 2025
Xeltis Raises €50M To Advance Tissue-Regenerating Dialysis Access As CMS Opens Door To New Options
Xeltis secured €50m to scale and market its aXess vascular access graft, a bioresorbable scaffold that transforms into a patient’s own living vessel. With EU regulatory review underway and US trials advancing, Xeltis sees new US Medicare rules as a major opening for alternative treatments.
Medtech Insight - December 10, 2025
Xeltis secured €50m to scale and market its aXess vascular access graft, a bioresorbable scaffold that transforms into a patient’s own living vessel. With EU regulatory review underway and US trials advancing, Xeltis sees new US Medicare rules as a major opening for alternative treatments.
Medtech Insight - December 10, 2025
C&D Pulls Curtain Down On Gummy Vitamin Gambit With Sale To Piping Rock Health
Decision on vitafusion and L’il Critters business planned by end of year, but Piping Rock Health provided incentive for C&D to opt for divestiture.
HBW Insight - December 10, 2025
Decision on vitafusion and L’il Critters business planned by end of year, but Piping Rock Health provided incentive for C&D to opt for divestiture.
HBW Insight - December 10, 2025
AAM Urges ‘Steady Leadership’ At FDA Following Pazdur’s Abrupt Resignation
With Richard Pazdur’s abrupt exit marking the fifth CDER leadership change in a year, the AAM is urging continuity and stability amid the ongoing turbulence.
Generics Bulletin - December 9, 2025
With Richard Pazdur’s abrupt exit marking the fifth CDER leadership change in a year, the AAM is urging continuity and stability amid the ongoing turbulence.
Generics Bulletin - December 9, 2025
Belgian Regulator Presses Roche Further Over Biosimilar Abuse Allegations
The Belgian Competition Authority has confirmed that it is escalating a complaint against Roche over alleged strategies used to delay biosimilar competition to rituximab and trastuzumab.
Generics Bulletin - December 9, 2025
The Belgian Competition Authority has confirmed that it is escalating a complaint against Roche over alleged strategies used to delay biosimilar competition to rituximab and trastuzumab.
Generics Bulletin - December 9, 2025
Hopewell Told Delay Is ‘Of Its Own Making’ As Cladribine Stay-Lifting Bid Fails
Delaware district court refuses to shorten 30-month stay, leaving Hopewell unable to launch its generic Mavenclad product.
Generics Bulletin - December 9, 2025
Delaware district court refuses to shorten 30-month stay, leaving Hopewell unable to launch its generic Mavenclad product.
Generics Bulletin - December 9, 2025
Biocon-BBL Integration: Can It Unmask The Biosimilars Arm’s Intrinsic Worth?
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Generics Bulletin - December 9, 2025
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Generics Bulletin - December 9, 2025
Wherever Medtech Goes, AI Will Have One Hand On The Steering Wheel
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
In Vivo - December 8, 2025
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
In Vivo - December 8, 2025
Biopharma In 2026: From Darwinian Reset To Disciplined Growth
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
In Vivo - December 8, 2025
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
In Vivo - December 8, 2025
As Lilly And Novo Nordisk Grow Their Obesity Empires, What Comes Next?
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
In Vivo - December 8, 2025
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
In Vivo - December 8, 2025